{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T14:52:48Z","timestamp":1779115968819,"version":"3.51.4"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2014,4,4]],"date-time":"2014-04-04T00:00:00Z","timestamp":1396569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2014,4,4]],"date-time":"2014-04-04T00:00:00Z","timestamp":1396569600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000024","name":"CIHR","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Foundation Fighting Blindness"},{"name":"McEwen Centre for Regenerative Medicine"},{"name":"Lowy Medical Research Institute MacTel Program"},{"DOI":"10.13039\/501100000015","name":"CCSRI","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000015","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EMBO Mol Med"],"published-print":{"date-parts":[[2014,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Current therapeutic antiangiogenic biologics used for the treatment of pathological ocular angiogenesis could have serious side effects due to their interference with normal blood vessel physiology. Here, we report the generation of novel antivascular endothelial growth factor\u2010A (VEGF) biologics, termed VEGF \u201cSticky\u2010traps,\u201d with unique properties that allow for local inhibition of angiogenesis without detectable systemic side effects. Using genetic and pharmacological approaches, we demonstrated that Sticky\u2010traps could locally inhibit angiogenesis to at least the same extent as the original VEGF\u2010trap that also gains whole\u2010body access. Sticky\u2010traps did not cause systemic effects, as shown by uncompromised wound healing and normal tracheal vessel density. Moreover, if injected intravitreally, recombinant Sticky\u2010trap remained localized to various regions of the eye, such as the inner\u2010limiting membrane and ciliary body, for prolonged time periods, without gaining access either to the photoreceptors\/choriocapillaris area or the circulation. These unique pharmacological characteristics of Sticky\u2010trap could allow for safe treatment of pathological angiogenesis in patients with diabetic retinopathy and retinopathy of pre\u2010maturity.<\/jats:p>","DOI":"10.1002\/emmm.201303708","type":"journal-article","created":{"date-parts":[[2014,4,8]],"date-time":"2014-04-08T12:06:29Z","timestamp":1396958789000},"page":"604-623","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Local acting Sticky\u2010trap inhibits vascular endothelial growth factor dependent pathological angiogenesis in the eye"],"prefix":"10.1038","volume":"6","author":[{"given":"Iacovos P","family":"Michael","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter D","family":"Westenskow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabiha","family":"Hacibekiroglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alissa Cohen","family":"Greenwald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian G","family":"Ballios","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihide","family":"Kurihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhijie","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen M","family":"Warren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Puzheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edith","family":"Aguilar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Donaldson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Marchetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Baba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samer M","family":"Hussein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hoon\u2010Ki","family":"Sung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M Luisa","family":"Iruela\u2010Arispe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James M","family":"Rini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Derek","family":"van der Kooy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Friedlander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andras","family":"Nagy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,4,4]]},"reference":[{"key":"BFEMMM201303708_CR1","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1097\/IAE.0b013e3181a2f42a","volume":"29","author":"M Abrishami","year":"2009","unstructured":"Abrishami M, Zarei\u2010Ghanavati S, Soroush D, Rouhbakhsh M, Jaafari MR, Malaekeh\u2010Nikouei B (2009) Preparation, characterization, and in vivo evaluation of nanoliposomes\u2010encapsulated bevacizumab (avastin) for intravitreal administration. Retina 29: 699\u2013703","journal-title":"Retina"},{"key":"BFEMMM201303708_CR2","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1002\/jgm.566","volume":"6","author":"S Agha\u2010Mohammadi","year":"2004","unstructured":"Agha\u2010Mohammadi S, O'Malley M, Etemad A, Wang Z, Xiao X, Lotze MT (2004) Second\u2010generation tetracycline\u2010regulatable promoter: repositioned tet operator elements optimize transactivator synergy while shorter minimal promoter offers tight basal leakiness. J Gene Med 6: 817\u2013828","journal-title":"J Gene Med"},{"key":"BFEMMM201303708_CR3","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMra1005073","volume":"366","author":"DA Antonetti","year":"2012","unstructured":"Antonetti DA, Klein R, Gardner TW (2012) Diabetic retinopathy. N Engl J Med 366: 1227\u20131239","journal-title":"N Engl J Med"},{"key":"BFEMMM201303708_CR4","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jaapos.2011.11.002","volume":"16","author":"RL Avery","year":"2012","unstructured":"Avery RL (2012) Bevacizumab (Avastin) for retinopathy of prematurity: wrong dose, wrong drug, or both? J AAPOS 16: 2\u20134","journal-title":"J AAPOS"},{"key":"BFEMMM201303708_CR5","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1016\/j.biomaterials.2009.12.004","volume":"31","author":"BG Ballios","year":"2010","unstructured":"Ballios BG, Cooke MJ, van der Kooy D, Shoichet MS (2010) A hydrogel\u2010based stem cell delivery system to treat retinal degenerative diseases. Biomaterials 31: 2555\u20132564","journal-title":"Biomaterials"},{"key":"BFEMMM201303708_CR6","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1167\/iovs.05-1096","volume":"47","author":"E Banin","year":"2006","unstructured":"Banin E, Dorrell MI, Aguilar E, Ritter MR, Aderman CM, Smith AC, Friedlander J, Friedlander M (2006) T2\u2010TrpRS inhibits preretinal neovascularization and enhances physiological vascular regrowth in OIR as assessed by a new method of quantification. Invest Ophthalmol Vis Sci 47: 2125\u20132134","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"BFEMMM201303708_CR7","doi-asserted-by":"crossref","first-page":"6616","DOI":"10.1158\/0008-5472.CAN-04-0401","volume":"64","author":"G Bocci","year":"2004","unstructured":"Bocci G, Man S, Green SK, Francia G, Ebos JM, du Manoir JM, Weinerman A, Emmenegger U, Ma L, Thorpe P et\u00a0al (2004) Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor\u20102 monoclonal antibodies. Cancer Res 64: 6616\u20136625","journal-title":"Cancer Res"},{"key":"BFEMMM201303708_CR8","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1159\/000262450","volume":"56","author":"S Boehm","year":"2010","unstructured":"Boehm S, Rothermundt C, Hess D, Joerger M (2010) Antiangiogenic drugs in oncology: a focus on drug safety and the elderly\u2014a mini\u2010review. Gerontology 56: 303\u2013309","journal-title":"Gerontology"},{"key":"BFEMMM201303708_CR9","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S1470-2045(09)70341-9","volume":"11","author":"D Bose","year":"2010","unstructured":"Bose D, Meric\u2010Bernstam F, Hofstetter W, Reardon DA, Flaherty KT, Ellis LM (2010) Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care. Lancet oncology 11: 373\u2013382","journal-title":"Lancet oncology"},{"key":"BFEMMM201303708_CR10","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1113\/jphysiol.2003.052738","volume":"555","author":"BV Bui","year":"2004","unstructured":"Bui BV, Fortune B (2004) Ganglion cell contributions to the rat full\u2010field electroretinogram. J Physiol 555: 153\u2013173","journal-title":"J Physiol"},{"key":"BFEMMM201303708_CR11","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/nm0603-653","volume":"9","author":"P Carmeliet","year":"2003","unstructured":"Carmeliet P (2003) Angiogenesis in health and disease. Nat Med 9: 653\u2013660","journal-title":"Nat Med"},{"key":"BFEMMM201303708_CR12","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1038\/nature04478","volume":"438","author":"P Carmeliet","year":"2005","unstructured":"Carmeliet P (2005) Angiogenesis in life, disease and medicine. Nature 438: 932\u2013936","journal-title":"Nature"},{"key":"BFEMMM201303708_CR13","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nrclinonc.2009.94","volume":"6","author":"HX Chen","year":"2009","unstructured":"Chen HX, Cleck JN (2009) Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol 6: 465\u2013477","journal-title":"Nat Rev Clin Oncol"},{"key":"BFEMMM201303708_CR14","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1200\/JCO.2006.06.3602","volume":"25","author":"LQ Chow","year":"2007","unstructured":"Chow LQ, Eckhardt SG (2007) Sunitinib: from rational design to clinical efficacy. J Clin Oncol 25: 884\u2013896","journal-title":"J Clin Oncol"},{"key":"BFEMMM201303708_CR15","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.ejca.2011.11.021","volume":"48","author":"J Cortes","year":"2012","unstructured":"Cortes J, Caralt M, Delaloge S, Cortes\u2010Funes H, Pierga JY, Pritchard KI, Bollag DT, Miles DW (2012) Safety of bevacizumab in metastatic breast cancer patients undergoing surgery. Eur J Cancer 48: 475\u2013481","journal-title":"Eur J Cancer"},{"key":"BFEMMM201303708_CR16","doi-asserted-by":"crossref","first-page":"F170","DOI":"10.1136\/archdischild-2011-301148","volume":"98","author":"BA Darlow","year":"2013","unstructured":"Darlow BA, Ells AL, Gilbert CE, Gole GA, Quinn GE (2013) Are we there yet? Bevacizumab therapy for retinopathy of prematurity. Arch Dis Child Fetal Neonatal Ed 98: F170\u2013F174","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"BFEMMM201303708_CR17","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.cell.2005.07.013","volume":"122","author":"S Ding","year":"2005","unstructured":"Ding S, Wu X, Li G, Han M, Zhuang Y, Xu T (2005) Efficient transposition of the piggyBac (PB) transposon in mammalian cells and mice. Cell 122: 473\u2013483","journal-title":"Cell"},{"key":"BFEMMM201303708_CR18","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S0042-6989(99)00203-5","volume":"40","author":"CJ Dong","year":"2000","unstructured":"Dong CJ, Hare WA (2000) Contribution to the kinetics and amplitude of the electroretinogram b\u2010wave by third\u2010order retinal neurons in the rabbit retina. Vision Res 40: 579\u2013589","journal-title":"Vision Res"},{"key":"BFEMMM201303708_CR19","first-page":"3500","volume":"43","author":"MI Dorrell","year":"2002","unstructured":"Dorrell MI, Aguilar E, Friedlander M (2002) Retinal vascular development is mediated by endothelial filopodia, a preexisting astrocytic template and specific R\u2010cadherin adhesion. Invest Ophthalmol Vis Sci 43: 3500\u20133510","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"BFEMMM201303708_CR20","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1172\/JCI35977","volume":"119","author":"MI Dorrell","year":"2009","unstructured":"Dorrell MI, Aguilar E, Jacobson R, Yanes O, Gariano R, Heckenlively J, Banin E, Ramirez GA, Gasmi M, Bird A et\u00a0al (2009) Antioxidant or neurotrophic factor treatment preserves function in a mouse model of neovascularization\u2010associated oxidative stress. J Clin Invest 119: 611\u2013623","journal-title":"J Clin Invest"},{"key":"BFEMMM201303708_CR21","doi-asserted-by":"crossref","first-page":"17069","DOI":"10.1073\/pnas.0708148104","volume":"104","author":"JM Ebos","year":"2007","unstructured":"Ebos JM, Lee CR, Christensen JG, Mutsaers AJ, Kerbel RS (2007) Multiple circulating proangiogenic factors induced by sunitinib malate are tumor\u2010independent and correlate with antitumor efficacy. Proc Natl Acad Sci USA 104: 17069\u201317074","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFEMMM201303708_CR22","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1038\/nrd1727","volume":"Suppl","author":"LM Ellis","year":"2005","unstructured":"Ellis LM (2005) Bevacizumab. Nat Rev Drug Discov Suppl: S8\u2013S9","journal-title":"Nat Rev Drug Discov"},{"key":"BFEMMM201303708_CR23","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1681\/ASN.2005080810","volume":"17","author":"V Eremina","year":"2006","unstructured":"Eremina V, Cui S, Gerber H, Ferrara N, Haigh J, Nagy A, Ema M, Rossant J, Jothy S, Miner JH et\u00a0al (2006) Vascular endothelial growth factor a signaling in the podocyte\u2010endothelial compartment is required for mesangial cell migration and survival. J Am Soc Nephrol 17: 724\u2013735","journal-title":"J Am Soc Nephrol"},{"key":"BFEMMM201303708_CR24","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1172\/JCI17423","volume":"111","author":"V Eremina","year":"2003","unstructured":"Eremina V, Sood M, Haigh J, Nagy A, Lajoie G, Ferrara N, Gerber HP, Kikkawa Y, Miner JH, Quaggin SE (2003) Glomerular\u2010specific alterations of VEGF\u2010A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 111: 707\u2013716","journal-title":"J Clin Invest"},{"key":"BFEMMM201303708_CR25","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/nrd1381","volume":"3","author":"N Ferrara","year":"2004","unstructured":"Ferrara N, Hillan KJ, Gerber HP, Novotny W (2004) Discovery and development of bevacizumab, an anti\u2010VEGF antibody for treating cancer. Nat Rev Drug Discov 3: 391\u2013400","journal-title":"Nat Rev Drug Discov"},{"key":"BFEMMM201303708_CR26","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nature04483","volume":"438","author":"N Ferrara","year":"2005","unstructured":"Ferrara N, Kerbel RS (2005) Angiogenesis as a therapeutic target. Nature 438: 967\u2013974","journal-title":"Nature"},{"key":"BFEMMM201303708_CR27","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrd2115","volume":"6","author":"J Folkman","year":"2007","unstructured":"Folkman J (2007) Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 6: 273\u2013286","journal-title":"Nat Rev Drug Discov"},{"key":"BFEMMM201303708_CR28","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/ncponc0342","volume":"2","author":"G Gasparini","year":"2005","unstructured":"Gasparini G, Longo R, Toi M, Ferrara N (2005) Angiogenic inhibitors: a new therapeutic strategy in oncology. Nat Clin Pract Oncol 2: 562\u2013577","journal-title":"Nat Clin Pract Oncol"},{"key":"BFEMMM201303708_CR29","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/S0167-5699(97)01172-9","volume":"18","author":"V Ghetie","year":"1997","unstructured":"Ghetie V, Ward ES (1997) FcRn: the MHC class I\u2010related receptor that is more than an IgG transporter. Immunol Today 18: 592\u2013598","journal-title":"Immunol Today"},{"key":"BFEMMM201303708_CR30","doi-asserted-by":"crossref","first-page":"41494","DOI":"10.1074\/jbc.M508739200","volume":"280","author":"SM Glaser","year":"2005","unstructured":"Glaser SM, Hughes IE, Hopp JR, Hathaway K, Perret D, Reff ME (2005) Novel antibody hinge regions for efficient production of CH2 domain\u2010deleted antibodies. J Biol Chem 280: 41494\u201341503","journal-title":"J Biol Chem"},{"key":"BFEMMM201303708_CR31","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nrclinonc.2009.110","volume":"6","author":"A Grothey","year":"2009","unstructured":"Grothey A, Galanis E (2009) Targeting angiogenesis: progress with anti\u2010VEGF treatment with large molecules. Nat Rev Clin Oncol 6: 507\u2013518","journal-title":"Nat Rev Clin Oncol"},{"key":"BFEMMM201303708_CR32","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1001\/archopht.1991.01080070117048","volume":"109","author":"A Hanneken","year":"1991","unstructured":"Hanneken A, de Juan E Jr, Lutty GA, Fox GM, Schiffer S, Hjelmeland LM (1991) Altered distribution of basic fibroblast growth factor in diabetic retinopathy. Arch Ophthalmol 109: 1005\u20131011","journal-title":"Arch Ophthalmol"},{"key":"BFEMMM201303708_CR33","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1111\/j.1651-2227.2011.02445.x","volume":"100","author":"AL Hard","year":"2011","unstructured":"Hard AL, Hellstrom A (2011) On safety, pharmacokinetics and dosage of bevacizumab in ROP treatment\u2014a review. Acta Paediatr 100: 1523\u20131527","journal-title":"Acta Paediatr"},{"key":"BFEMMM201303708_CR34","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/nrclinonc.2009.52","volume":"6","author":"VL Heath","year":"2009","unstructured":"Heath VL, Bicknell R (2009) Anticancer strategies involving the vasculature. Nat Rev Clin Oncol 6: 395\u2013404","journal-title":"Nat Rev Clin Oncol"},{"key":"BFEMMM201303708_CR35","doi-asserted-by":"crossref","first-page":"11393","DOI":"10.1073\/pnas.172398299","volume":"99","author":"J Holash","year":"2002","unstructured":"Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, Boland P, Leidich R, Hylton D, Burova E et\u00a0al (2002) VEGF\u2010Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 99: 11393\u201311398","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFEMMM201303708_CR36","doi-asserted-by":"crossref","first-page":"26031","DOI":"10.1016\/S0021-9258(18)35712-0","volume":"267","author":"KA Houck","year":"1992","unstructured":"Houck KA, Leung DW, Rowland AM, Winer J, Ferrara N (1992) Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J Biol Chem 267: 26031\u201326037","journal-title":"J Biol Chem"},{"key":"BFEMMM201303708_CR37","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1056\/NEJMra0801537","volume":"358","author":"RD Jager","year":"2008","unstructured":"Jager RD, Mieler WF, Miller JW (2008) Age\u2010related macular degeneration. N Engl J Med 358: 2606\u20132617","journal-title":"N Engl J Med"},{"key":"BFEMMM201303708_CR38","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1517\/17425247.4.4.371","volume":"4","author":"KG Janoria","year":"2007","unstructured":"Janoria KG, Gunda S, Boddu SH, Mitra AK (2007) Novel approaches to retinal drug delivery. Expert Opin Drug Deliv 4: 371\u2013388","journal-title":"Expert Opin Drug Deliv"},{"key":"BFEMMM201303708_CR39","doi-asserted-by":"crossref","first-page":"H560","DOI":"10.1152\/ajpheart.00133.2005","volume":"290","author":"T Kamba","year":"2006","unstructured":"Kamba T, Tam BY, Hashizume H, Haskell A, Sennino B, Mancuso MR, Norberg SM, O'Brien SM, Davis RB, Gowen LC et\u00a0al (2006) VEGF\u2010dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol 290: H560\u2013H576","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"BFEMMM201303708_CR40","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1056\/NEJMra0706596","volume":"358","author":"RS Kerbel","year":"2008","unstructured":"Kerbel RS (2008) Tumor angiogenesis. N Engl J Med 358: 2039\u20132049","journal-title":"N Engl J Med"},{"key":"BFEMMM201303708_CR41","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ccr.2010.07.001","volume":"18","author":"YJ Koh","year":"2010","unstructured":"Koh YJ, Kim HZ, Hwang SI, Lee JE, Oh N, Jung K, Kim M, Kim KE, Kim H, Lim NK et\u00a0al (2010) Double antiangiogenic protein, DAAP, targeting VEGF\u2010A and angiopoietins in tumor angiogenesis, metastasis, and vascular leakage. Cancer Cell 18: 171\u2013184","journal-title":"Cancer Cell"},{"key":"BFEMMM201303708_CR42","doi-asserted-by":"crossref","first-page":"28045","DOI":"10.1074\/jbc.M700319200","volume":"282","author":"D Krilleke","year":"2007","unstructured":"Krilleke D, DeErkenez A, Schubert W, Giri I, Robinson GS, Ng YS, Shima DT (2007) Molecular mapping and functional characterization of the VEGF164 heparin\u2010binding domain. J Biol Chem 282: 28045\u201328056","journal-title":"J Biol Chem"},{"key":"BFEMMM201303708_CR43","doi-asserted-by":"crossref","first-page":"4213","DOI":"10.1172\/JCI65157","volume":"122","author":"T Kurihara","year":"2012","unstructured":"Kurihara T, Westenskow PD, Bravo S, Aguilar E, Friedlander M (2012) Targeted deletion of Vegfa in adult mice induces vision loss. J Clin Invest 122: 4213\u20134217","journal-title":"J Clin Invest"},{"key":"BFEMMM201303708_CR44","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.canlet.2006.08.015","volume":"249","author":"MR Ladomery","year":"2007","unstructured":"Ladomery MR, Harper SJ, Bates DO (2007) Alternative splicing in angiogenesis: the vascular endothelial growth factor paradigm. Cancer Lett 249: 133\u2013142","journal-title":"Cancer Lett"},{"key":"BFEMMM201303708_CR45","doi-asserted-by":"crossref","first-page":"5004","DOI":"10.1073\/pnas.1218620110","volume":"110","author":"Z Li","year":"2013","unstructured":"Li Z, Michael IP, Zhou D, Nagy A, Rini JM (2013) Simple piggyBac transposon\u2010based mammalian cell expression system for inducible protein production. Proc Natl Acad Sci USA 110: 5004\u20135009","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFEMMM201303708_CR46","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/00006982-200504000-00010","volume":"25","author":"N Matsunaga","year":"2005","unstructured":"Matsunaga N, Ozeki H, Hirabayashi Y, Shimada S, Ogura Y (2005) Histopathologic evaluation of the internal limiting membrane surgically excised from eyes with diabetic maculopathy. Retina 25: 311\u2013316","journal-title":"Retina"},{"key":"BFEMMM201303708_CR47","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1172\/JCI17189","volume":"111","author":"SE Maynard","year":"2003","unstructured":"Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE et\u00a0al (2003) Excess placental soluble fms\u2010like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 111: 649\u2013658","journal-title":"J Clin Invest"},{"key":"BFEMMM201303708_CR48","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","volume":"364","author":"HA Mintz\u2010Hittner","year":"2011","unstructured":"Mintz\u2010Hittner HA, Kennedy KA, Chuang AZ (2011) Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med 364: 603\u2013615","journal-title":"N Engl J Med"},{"key":"BFEMMM201303708_CR49","doi-asserted-by":"crossref","first-page":"5702","DOI":"10.1073\/pnas.87.15.5702","volume":"87","author":"BM Mueller","year":"1990","unstructured":"Mueller BM, Reisfeld RA, Gillies SD (1990) Serum half\u2010life and tumor localization of a chimeric antibody deleted of the CH2 domain and directed against the disialoganglioside GD2. Proc Natl Acad Sci USA 87: 5702\u20135705","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFEMMM201303708_CR50","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1161\/01.ATV.0000137189.22999.3f","volume":"24","author":"EM Munoz","year":"2004","unstructured":"Munoz EM, Linhardt RJ (2004) Heparin\u2010binding domains in vascular biology. Arterioscler Thromb Vac Biol 24: 1549\u20131557","journal-title":"Arterioscler Thromb Vac Biol"},{"key":"BFEMMM201303708_CR51","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1161\/CIRCULATIONAHA.110.992230","volume":"124","author":"B Nazer","year":"2011","unstructured":"Nazer B, Humphreys BD, Moslehi J (2011) Effects of novel angiogenesis inhibitors for the treatment of cancer on the cardiovascular system: focus on hypertension. Circulation 124: 1687\u20131691","journal-title":"Circulation"},{"key":"BFEMMM201303708_CR52","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1038\/nm1202-794","volume":"8","author":"AG Niethammer","year":"2002","unstructured":"Niethammer AG, Xiang R, Becker JC, Wodrich H, Pertl U, Karsten G, Eliceiri BP, Reisfeld RA (2002) A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat Med 8: 1369\u20131375","journal-title":"Nat Med"},{"key":"BFEMMM201303708_CR53","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2353\/ajpath.2007.061237","volume":"171","author":"K Nishijima","year":"2007","unstructured":"Nishijima K, Ng YS, Zhong L, Bradley J, Schubert W, Jo N, Akita J, Samuelsson SJ, Robinson GS, Adamis AP et\u00a0al (2007) Vascular endothelial growth factor\u2010A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol 171: 53\u201367","journal-title":"Am J Pathol"},{"key":"BFEMMM201303708_CR54","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1038\/nm744","volume":"8","author":"A Otani","year":"2002","unstructured":"Otani A, Kinder K, Ewalt K, Otero FJ, Schimmel P, Friedlander M (2002) Bone marrow\u2010derived stem cells target retinal astrocytes and can promote or inhibit retinal angiogenesis. Nat Med 8: 1004\u20131010","journal-title":"Nat Med"},{"key":"BFEMMM201303708_CR55","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1089\/jop.2010.0158","volume":"27","author":"CK Pan","year":"2011","unstructured":"Pan CK, Durairaj C, Kompella UB, Agwu O, Oliver SC, Quiroz\u2010Mercado H, Mandava N, Olson JL (2011) Comparison of long\u2010acting bevacizumab formulations in the treatment of choroidal neovascularization in a rat model. J Ocul Pharmacol Ther 27: 219\u2013224","journal-title":"J Ocul Pharmacol Ther"},{"key":"BFEMMM201303708_CR56","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s10456-011-9249-6","volume":"15","author":"N Papadopoulos","year":"2012","unstructured":"Papadopoulos N, Martin J, Ruan Q, Rafique A, Rosconi MP, Shi E, Pyles EA, Yancopoulos GD, Stahl N, Wiegand SJ (2012) Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis 15: 171\u2013185","journal-title":"Angiogenesis"},{"key":"BFEMMM201303708_CR57","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1091\/mbc.4.12.1317","volume":"4","author":"JE Park","year":"1993","unstructured":"Park JE, Keller GA, Ferrara N (1993) The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix\u2010bound VEGF. Mol Biol Cell 4: 1317\u20131326","journal-title":"Mol Biol Cell"},{"key":"BFEMMM201303708_CR58","doi-asserted-by":"crossref","first-page":"11082","DOI":"10.1074\/jbc.M111.331140","volume":"287","author":"MW Parker","year":"2012","unstructured":"Parker MW, Xu P, Li X, Vander Kooi CW (2012) Structural basis for selective vascular endothelial growth factor\u2010A (VEGF\u2010A) binding to neuropilin\u20101. J Biol Chem 287: 11082\u201311089","journal-title":"J Biol Chem"},{"key":"BFEMMM201303708_CR59","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/gt.2008.115","volume":"16","author":"P Pechan","year":"2009","unstructured":"Pechan P, Rubin H, Lukason M, Ardinger J, DuFresne E, Hauswirth WW, Wadsworth SC, Scaria A (2009) Novel anti\u2010VEGF chimeric molecules delivered by AAV vectors for inhibition of retinal neovascularization. Gene Ther 16: 10\u201316","journal-title":"Gene Ther"},{"key":"BFEMMM201303708_CR60","doi-asserted-by":"crossref","first-page":"e136","DOI":"10.1111\/j.1755-3768.2009.01572.x","volume":"88","author":"P Petrou","year":"2010","unstructured":"Petrou P, Georgalas I, Giavaras G, Anastasiou E, Ntana Z, Petrou C (2010) Early loss of pregnancy after intravitreal bevacizumab injection. Acta Ophthalmol (Copenh) 88: e136","journal-title":"Acta Ophthalmol (Copenh)"},{"key":"BFEMMM201303708_CR61","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1242\/jcs.114.5.853","volume":"114","author":"CJ Robinson","year":"2001","unstructured":"Robinson CJ, Stringer SE (2001) The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J Cell Sci 114: 853\u2013865","journal-title":"J Cell Sci"},{"key":"BFEMMM201303708_CR62","first-page":"2337","volume":"118","author":"L Scheppke","year":"2008","unstructured":"Scheppke L, Aguilar E, Gariano RF, Jacobson R, Hood J, Doukas J, Cao J, Noronha G, Yee S, Weis S et\u00a0al (2008) Retinal vascular permeability suppression by topical application of a novel VEGFR2\/Src kinase inhibitor in mice and rabbits. J Clin Invest 118: 2337\u20132346","journal-title":"J Clin Invest"},{"key":"BFEMMM201303708_CR63","doi-asserted-by":"crossref","first-page":"5537","DOI":"10.4049\/jimmunol.0803742","volume":"182","author":"MM Seavey","year":"2009","unstructured":"Seavey MM, Maciag PC, Al\u2010Rawi N, Sewell D, Paterson Y (2009) An anti\u2010vascular endothelial growth factor receptor 2\/fetal liver kinase\u20101 Listeria monocytogenes anti\u2010angiogenesis cancer vaccine for the treatment of primary and metastatic Her\u20102\/neu+ breast tumors in a mouse model. J Immunol 182: 5537\u20135546","journal-title":"J Immunol"},{"key":"BFEMMM201303708_CR64","first-page":"101","volume":"35","author":"LE Smith","year":"1994","unstructured":"Smith LE, Wesolowski E, McLellan A, Kostyk SK, D'Amato R, Sullivan R, D'Amore PA (1994) Oxygen\u2010induced retinopathy in the mouse. Invest Ophthalmol Vis Sci 35: 101\u2013111","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"BFEMMM201303708_CR65","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.mayocp.2011.10.001","volume":"87","author":"MW Stewart","year":"2012","unstructured":"Stewart MW (2012) The expanding role of vascular endothelial growth factor inhibitors in ophthalmology. Mayo Clin Proc 87: 77\u201388","journal-title":"Mayo Clin Proc"},{"key":"BFEMMM201303708_CR66","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nrd3700","volume":"11","author":"MW Stewart","year":"2012","unstructured":"Stewart MW, Grippon S, Kirkpatrick P (2012a) Aflibercept. Nat Rev Drug Discov 11: 269\u2013270","journal-title":"Nat Rev Drug Discov"},{"key":"BFEMMM201303708_CR67","first-page":"434","volume":"32","author":"MW Stewart","year":"2012","unstructured":"Stewart MW, Rosenfeld PJ, Penha FM, Wang F, Yehoshua Z, Bueno\u2010Lopez E, Lopez PF (2012b) Pharmacokinetic rationale for dosing every 2\u00a0weeks versus 4\u00a0weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap\u2010eye). Retina 32: 434\u2013457","journal-title":"Retina"},{"key":"BFEMMM201303708_CR68","doi-asserted-by":"crossref","first-page":"5874","DOI":"10.1073\/pnas.1200447109","volume":"109","author":"K Sun","year":"2012","unstructured":"Sun K, Wernstedt Asterholm I, Kusminski CM, Bueno AC, Wang ZV, Pollard JW, Brekken RA, Scherer PE (2012) Dichotomous effects of VEGF\u2010A on adipose tissue dysfunction. Proc Natl Acad Sci USA 109: 5874\u20135879","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFEMMM201303708_CR69","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1159\/000101344","volume":"91","author":"B Thebaud","year":"2007","unstructured":"Thebaud B (2007) Angiogenesis in lung development, injury and repair: implications for chronic lung disease of prematurity. Neonatology 91: 291\u2013297","journal-title":"Neonatology"},{"key":"BFEMMM201303708_CR70","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1152\/japplphysiol.00589.2004","volume":"98","author":"MC Tissot van Patot","year":"2005","unstructured":"Tissot van Patot MC, Leadbetter G, Keyes LE, Bendrick\u2010Peart J, Beckey VE, Christians U, Hackett P (2005) Greater free plasma VEGF and lower soluble VEGF receptor\u20101 in acute mountain sickness. J Appl Physiol 98: 1626\u20131629","journal-title":"J Appl Physiol"},{"key":"BFEMMM201303708_CR71","doi-asserted-by":"crossref","first-page":"7963","DOI":"10.1073\/pnas.130192197","volume":"97","author":"S Urlinger","year":"2000","unstructured":"Urlinger S, Baron U, Thellmann M, Hasan MT, Bujard H, Hillen W (2000) Exploring the sequence space for tetracycline\u2010dependent transcriptional activators: novel mutations yield expanded range and sensitivity. Proc Natl Acad Sci USA 97: 7963\u20137968","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFEMMM201303708_CR72","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/nrc2152","volume":"7","author":"HM Verheul","year":"2007","unstructured":"Verheul HM, Pinedo HM (2007) Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer 7: 475\u2013485","journal-title":"Nat Rev Cancer"},{"key":"BFEMMM201303708_CR73","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/nrd2130","volume":"5","author":"S Wilhelm","year":"2006","unstructured":"Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith RA, Schwartz B, Simantov R, Kelley S (2006) Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 5: 835\u2013844","journal-title":"Nat Rev Drug Discov"},{"key":"BFEMMM201303708_CR74","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1038\/nature07863","volume":"458","author":"K Woltjen","year":"2009","unstructured":"Woltjen K, Michael IP, Mohseni P, Desai R, Mileikovsky M, Hamalainen R, Cowling R, Wang W, Liu P, Gertsenstein M et\u00a0al (2009) piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells. Nature 458: 766\u2013770","journal-title":"Nature"}],"container-title":["EMBO Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1002\/emmm.201303708.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/emmm.201303708","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1002\/emmm.201303708\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.embopress.org\/doi\/pdf\/10.1002\/emmm.201303708","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1002\/emmm.201303708.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T06:08:17Z","timestamp":1779084497000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1002\/emmm.201303708"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,4]]},"references-count":74,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,5,1]]}},"alternative-id":["BFEMMM201303708"],"URL":"https:\/\/doi.org\/10.1002\/emmm.201303708","relation":{},"ISSN":["1757-4676","1757-4684"],"issn-type":[{"value":"1757-4676","type":"print"},{"value":"1757-4684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,4]]},"assertion":[{"value":"7 December 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2014","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2014","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2014","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}